SensiVida Medical Technologies, Inc. Digital Allergy Test System Receives Extremely Favorable Feedback From Allergists

HENRIETTA, NY--(Marketwire - May 16, 2011) -

SensiVida Medical Technologies Inc. (PINKSHEETS: SVMT), a developer and provider of digital diagnostic technologies and devices, announced today encouraging findings from a recent March 2011 survey of allergists on their reaction to the SensiVida Digital Allergy Test System.

The SensiVida Digital Allergy Test System employs a compact one-time use cartridge preloaded with 40 different allergens and ultra-fine microneedles. The allergens are painlessly delivered to the skin in a single, rapid motion. A digital imaging system supported with proprietary image processing technology captures images of the reactions in real-time and transfers them to a computer for analysis. Digital reports are automatically created which can be printed or loaded into electronic medical records (EMR).

Newburyport, MA, based Scott Taylor Associates (STA) was retained by SensiVida to assess clinical and economic drivers that will influence product adoption by allergists. To accomplish this task, STA conducted in-depth telephone interviews with 20 allergists from across the U.S. to gather their perspectives of SensiVida’s Digital Allergy Test System. Interviews consisted of questions that discussed clinical utilization, standards of care and pricing, as well as an evaulation of SensiVida’s product profile.

Allergists were asked to rate their reaction to the various components of the Digital Allergy Test System. Overall, the allergists provided strong positive feedback; they particularly liked the data management component for its ability to reduce human error, to provide consistent, standardized results and to connect to electronic medical records. The pricing also had very favorable scores, indicating a strong potential to sell at the prices suggested.

The following comments, made by the allergists during the interviews, highlight the benefits they perceive in the SensiVida Allergy Testing System:
“Time savings, allowing to test more patients daily";
“Could increase nurses’ time spent on other activities due to less time on testing";
“Results go directly into the EMR -- saves time and labor";
“More automation can reduce human error";
“Less pain for the patients.”

“The overall response by allergists to our Digital Allergy Test System was extremely positive,” said Margy Lydon, Chief Operating Officer of SensiVida Medical Technologies. “Allergists particularly liked the time savings, automatic digital records and the more accurate and consistent test data they will obtain with our system. The survey results clearly correspond with data obtained in prior business research activities and trade conferences, indicating that allergists favor our product concept as a more accurate, more profitable alternative to standard Skin Prick Testing.”

In 2010, STA completed a survey of health insurance Payers on behalf of SensiVida. (See: Marketwire, Oct. 6, 2010 - http://www.marketwire.com/press-release/sensivida-medical-technologies-inc-announces-favorable-findings-from-reimbursement-assessment-1330504.htm) All the Payers interviewed unanimously stated that the SensiVida Digital Allergy Test System would be covered by their respective plans using existing codes. These findings, coupled with the favorable reaction from allergists, indicate a strong potential that the allergist community will adopt the Digital Allergy Test System.

About SensiVida Medical Technologies, Inc.

SensiVida is a developer and provider of digital diagnostic devices with proprietary, microsystems-based technology that automates bio-sensing and data acquisition while minimizing patient discomfort. The Company’s optical-digital platform technology addresses a number of multi-billion dollar market opportunities: allergy testing, pain-free automated glucose monitors, blood coagulation testing, TB testing, cholesterol monitoring, and more.

SensiVida has an exclusive worldwide license to nine pending patents. In addition to the SensiVida allergy test, the product pipeline, based on the same microsystem and image processing technology, includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient’s test schedule, automatically recording the patient’s glucose level without pain, bio-fouling or clogging. For more information about SensiVida, please visit www.sensividamedical.com

About Scott Taylor Associates, Inc.

STA is a healthcare consulting company that provides strategy, reimbursement, FDA/Quality, market research, business analysis and strategic planning support consulting to medical device, pharmaceutical and diagnostic product clients worldwide. Additionally, STA provides call center support services, including technical and customer support, order processing, and product/literature fulfillment services to medical device companies.

Forward -Looking Statements:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company’s ability to implement its long range business plan for various applications of its technology; the company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company’s reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company’s financial position. See the Company’s most recent Quarterly Report on Form 10Q and related 8-K filings.